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Goals and Objectives
Participants will be able to
– Explain the pathophysiology leading to the
pulmonary complications of cystic fibrosis
– Recognize the clinical presentation of the
pulmonary complications of cystic fibrosis
– Formulate a treatment plan for the pulmonary
complications of cystic fibrosis

CFF Consensus Guidelines
• Am J Respir Crit Care Med Vol 182. pp
298–306, 2010
• Delphi methodology
– PICO questions developed by CFF
Pulmonary Guidelines Committee
– 42 CF clinicians, 6 interventional radiologists,
7 transplant surgeons
– Literature search (1985-2009)

– Questionnaire
• Series of statements on Hem and Pntx
• Likert scale of 0-10 (Hem) or 0-9 (Pntx)
representing complete disagreement to complete
agreement
• Completed, refined, completed a second time
• Consensus report generated

– Consensus Definitions
• Perfect = all respondents agree
• Very Good = Median and middle 50% (IQR) of
respondents are found at one integer (e.g., median
and IQR are both at 8) or 80% of respondents are
within one integer of the median (e.g., median is 8,
80% of respondents are from 7–9)

• Good = 50% of respondents are within one integer
of the median (e.g., median is 8, 50% of
respondents are from 7–9) or 80% of respondents
are within two integers of the median (e.g. median
is 7, 80% of respondents are from 5–9)
• Some = 50% of respondents are within one
integer of the median (e.g., median is 8, 50% of
respondents are from 7–9) or 80% of respondents
are within two integers of the median (e.g. median
is 7, 80% of respondents are from 5–9)
• None = All other responses

– Subsequent summaries must have “Good”
agreement and IQR of > 5

EPIDEMIOLOGY AND PATHOPHYSIOLOGY
HEMOPTYSIS

• 2008 Israeli review reported 9.1% of
patients had hemoptysis in a 5-year
period
• 2005 US review
– 4.1% of all patients will suffer massive
hemoptysis during their lifetime
– average annual incidence is 0.87% (1 in 115
patients per year)
• Median age for massive hemoptysis is 23 years

• 75% of cases occur in patients > 18 years of age

• Chronic inflammation leads to bronchial
artery hypertrophy and angiogenesis
– High pressure system
– Thin-walled vessels

• Acute infection or pulmonary
exacerbation often associated with
hemoptysis
– Association with SA

• Definition
– Scant = blood streaking or < 20 ml/day
– Mild-moderate = > 20 ml/day but < 240
ml/day
– Massive = 240 ml/day or recurrent bleeding
of substantial volumes >100 ml/day (> 500
ml/day in adults sometimes used)

DIAGNOSIS OF
HEMOPTYSIS

• Coughing up blood or blood-stained
mucus
• “Pseudohemoptysis”
– Upper respiratory or GI source
– Fictitious

• CXR and CT rarely helpful in identifying
vessel involved
• Bronchial artery angiography most
helpful

THERAPY
HEMOPTYSIS

• CFF Guidelines
– First episode of scant, persistent scant, mildto-moderate, or massive hemoptysis
requires contact with provider
– Massive hemoptysis requires admission
– Mild-to-moderate or massive hemoptysis
requires antibiotic therapy
– NSAIDs should be stopped for any
hemoptysis
– Unstable patients with massive hemoptysis
should have BAE

– Airway clearance therapy
• Good consensus that scant hemoptysis did not
require discontinuation of ACT
• Poor consensus and no recommendation for
mild-moderate hemoptysis
• Better consensus that ACT be discontinued for
massive hemoptysis

– Aerosol therapy
• Good consensus that scant hemoptysis did not
require discontinuation of aerosol therapy
• Poor consensus and no recommendation for
mild-moderate hemoptysis
• Good consensus that hypertonic saline should be
discontinued but no consensus on other therapy
for massive hemoptysis

• Medical management
– Assess CBC and coagulation studies
– Discontinue any medications associated
with anticoagulation
– Consider treatment with vitamin K,
tranexamic acid, empiric antibiotics
• Tranexamic acid prevents plasmin-tPA complex
from binding to fibrin, inhibiting fibrinolysis; Q4-8
dosing (oral or IV); can clot central lines

– Supportive care (oxygen, fluids, transfusion)

• Bronchial artery embolization
– Demonstrated efficacy; often limited by
resources; not risk-free

EPIDEMIOLOGY AND PATHOPHYSIOLOGY
PNEUMOTHORAX

• 3.4% of individuals will experience a
pneumothorax during their lifetime
– Average annual incidence of 0.64% (1 in
167 patients per year)
– Median age for pneumothorax was 21 years
• 72.4% occurred in patients > 18 years of age

– Risk factors
• 75% occur in patients with an FEV1 less than
40% predicted
• Other indicators of advanced disease (PA,
Cepacia, medications, etc.)

– 46% of patients with contralateral recurrence
– 48.6% 2-year mortality

• Pathophysiogy
– Air-trapping caused by obstruction
– Alveolar pressure exceeds interstitial
pressure
– Air movement from alveolus to interstitium
– Rupture of air into mediastinal or pleural
space

DIAGNOSIS OF
PNEUMOTHORAX

• Symptoms
– Acute onset chest pain
– Dyspnea
– Cyanosis

• Diagnostic imaging
– CXR
– CT

THERAPY
PNEUMOTHORAX

• CFF Guidelines
– Small, stable pneumothorax can be
observed; large pneumothorax requires
admission
– Small unstable and any large pneumothorax
requires a chest tube
– Any recurrent pneumothorax requires
surgical pleurodesis
– BiPAP should be discontinued for any
pneumothorax
– Air-travel, weight lifting, and PFT are
prohibited for 2 weeks for any pneumothorax

– Airway clearance therapy
• Poor consensus overall except that positive
pressure ACTs should generally be avoided and
that absolutely should be avoided for large Pntx

– Aerosol therapy
• Good consensus that aerosol therapy should be
continued with the exception of hypertonic
saline, for which there was no consensus

EVERYTHING ELSE

• Respiratory Failure
– Epidemiology & Pathophysiology
• Hypoxemia and hypercarbia caused by
ventilation-perfusion mismatch
• Muscle fatigue

– Diagnosis
• Pulse oximetry
• Blood gas sampling

– Therapy
•
•
•
•

Acute care for pulmonary exacerbation
Oxygen supplementation
Ventilatory support
Lung Transplant
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Thank You!
Questions?
Discussion?

